Bibliography
- BADESCH DB, McLAUGHLIN VV, DELCROIX M et al.: Prostanoid therapy for pulmonary arterial hypertension. J. Am. Coll. CardioL (2004) 43(12 Suppl. S):56S–61S.
- LIU C, CHENG J: Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst. Rev. (2005) 1:CD004434.
- KANTHAPILLAI P, LASSERSON T, WALTERS E: Sildenatil for pulmonary hypertension. Cochrane Database Syst. Rev. (2004) 4:CD003562.
- LOWSON SM: Inhaled alternatives to nitric oxide. Crit. Care Med. (2005) 33\(Suppl. 3):5188–5195.
- SWARD K, MITA M, WILSON DP et aL: The role of RhoA and Rho-associated in vascular smooth muscle contraction. Curr. Hypertens. Rep. (2003) 5:66–72.
- NAGAOKA T, MORIO Y, CASANOVA N et al.: Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am. J. PhysioL Lung MoL PhysioL (2004) 287:L665–L672.
- NAGAOKA T, FAGAN KA, GEBB SA et al.: Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 171:494–499.
- FUKUMOTO Y, MATOBA T, ITO A et al.: Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart (2005) 91:391–392.
- ABE K, SHIMOKAWA H, K et al.: Long-term treatment with a Rho-kinase inhibitor improved monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. (2004) 94:385–393.
Websites
- http://www.nhlbi.nih.gov/health/dci/ Diseases/pah/pah_all.html Blood, Lung and Heart Institute's pulmonary hypertension index.